Detalhe da pesquisa
1.
Growth factors contribute to the mediation of angiogenic capacity of glioma-associated mesenchymal stem cells.
Oncol Lett;
21(3): 215, 2021 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33552293
2.
Cell fusion in cancer hallmarks: Current research status and future indications.
Oncol Lett;
22(1): 530, 2021 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34055095
3.
CD90low glioma-associated mesenchymal stromal/stem cells promote temozolomide resistance by activating FOXS1-mediated epithelial-mesenchymal transition in glioma cells.
Stem Cell Res Ther;
12(1): 394, 2021 07 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34256854
4.
Roles of long non-coding RNAs in the hallmarks of glioma.
Oncol Lett;
20(4): 83, 2020 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32863916
5.
Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas.
Stem Cell Res Ther;
9(1): 228, 2018 08 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30143053
6.
CD90 determined two subpopulations of glioma-associated mesenchymal stem cells with different roles in tumour progression.
Cell Death Dis;
9(11): 1101, 2018 10 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30368520
7.
Correction to: CD90low glioma-associated mesenchymal stromal/stem cells promote temozolomide resistance by activating FOXS1-mediated epithelial-mesenchymal transition in glioma cells.
Stem Cell Res Ther;
12(1): 493, 2021 Sep 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34488861